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Abstract
The increasing use of genomics to define the pattern of actionable mutations and to test and validate new therapies
for individual cancer patients, and the growing application of liquid biopsy to dynamically track tumor evolution and
to adapt molecularly targeted therapy according to the emergence of tumor clonal variants is shaping modern
medical oncology., In order to better describe this new therapeutic paradigm we propose the term “Liquid dynamic
medicine” in the place of “Personalized or Precision medicine”. Clinical validation of the “Liquid dynamic medicine”
approach is best captured by N-of-1 trials where each patient acts as tester and control of truly personalized therapies.
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Background
In year 1999, Langreth and Waldholz used for the first
time used the terminology “personalized medicine” with
the aim indeed to identify “the right drug for each unique
genetic profile” [1]. Since then, the expressions “personal-
ized medicine”, or “precision medicine” (PM) have be-
come widely used in oncology to indicate medical
procedures by which patients receive tailored interven-
tions based on the genetic alterations found in their tu-
mors [2]. Although attempts to attain a unique definition
of PM have been made, various definitions now exist in
the literature which share the common concept that a
genetic test is at the basis of every PM treatment and that
this genetic test is required to stratify patients into sub-
groups which may or may not take advantage from a med-
ical treatment [3, 4]. It is in this context that PM is strictly
based on a molecular investigation. However, this does
not necessarily correspond to personalization of the care
tailored to the patients’ preferences and choices, which
often is the cause of confusion [5]. Hence, today the term
personalized or precision medicine is interpreted in vari-
ous ways by the media, health care professionals or pa-
tients [6]. Perhaps the most appropriate definition,
because it is the most widely used, is the National Insti-
tutes of Health’s definition: “The use of the combined
knowledge (genetic or otherwise) about a person to pre-
dict disease susceptibility, disease prognosis, or treatment
response and thereby improve a person’s health” [6].
Genomic biomarker-driven therapy
Holding onto the concept of PM as a genetic biomarker-
driven treatment, an increasing number of cases have
been accumulated in recent years. Of these, the most
cited examples include the use of imatinib for BCR-ABL
positive chronic myeloid leukemia or c-Kit positive
gastrointestinal tumors [7], anti-HER2 antibodies for
HER2 amplified breast or gastric cancers [8], anti-EGFR
antibodies for non KRAS mutated colorectal cancers [9],
small molecule EGFR inhibitors for EGFR mutated lung
cancers [10, 11], BRAF inhibitors or combinations of
BRAF and MEK inhibitors for melanoma patients bear-
ing BRAF mutations in their tumors [12] or ALK inhibi-
tors for ALK or ROS translocations in lung cancer [13].
Conventional Phase III trials have shown that when pa-
tients are stratified by the use of a genetic test known as
“companion diagnostics” to receive targeted therapy,
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patients testing “positive” for the biomarker experience a
superior clinical benefit in terms of progression free sur-
vival and/or overall survival as compared to those testing
“negative” for the same biomarker. This approach has
often allowed accelerated market approval for the corre-
sponding drugs [14]. It must be added that meta-
analyses including a total of approximately 85,000 pa-
tients have confirmed that the genetic biomarker-driven
patient selection is safe and has been associated with im-
provements in all outcome variables [15–17]. In
addition, it would be considerate that the increasing use
of this molecular approach in both cancer research and
clinical practice, bring to a higher expense for target
drugs, which are compensated by a less overall costs for
the Health System coming from the better patient out-
come and reduction of hospital admissions.
However, strictly speaking, these examples of PM are
not truly considered “personalized medicine” since they
are not tailored to individual patients, but rather to sub-
groups of patients sharing only one of the several genetic
alterations present in their tumors.
The genetic biomarker-driven concept of PM has been
challenged by a series of facts and evidence. Firstly, the
presence or absence of the specific biomarker does not al-
ways result in biological and clinical sensitivity to the cor-
responding drug. For example, a subset of lung cancer
patients which do not bear activating EGFR mutations can
achieve clinical responses to EGFR inhibitors [18], or also
a good proportion of BRAF mutated melanoma patients
do not respond to BRAF inhibitors [19]. The case of BRAF
mutations is even more intriguing because activating
oncogenic BRAF mutations are found in several other tu-
mors, including colorectal, thyroid, lung cancer but in the
majority of those cases they are not predictive of drug re-
sponse to the same BRAF inhibitors as in melanoma.
Mechanistic explanations to these findings are emerging
and reside in the presence of additional genetic or epigen-
etic alterations which may create from case to case “favor-
able” or “unfavorable” contexts to the action of a specific
target therapy. This brings us to the second line of evi-
dence: tumors are in general highly heterogeneous and
mutated in several driver genes.
Interpatient and intrapatient heterogeneity
The first level of heterogeneity is interpatient heterogeneity.
Tumors of the same histological origin but deriving from
different patients, are genetically (and epigenetically) altered
and harbor a large number of molecular alterations result-
ing from an evolutionary process that starts from normal
cells through the clonal expansion of cells capable of over-
coming the physiological control of cell growth. At this
point the necessity, for true “precision oncology”, is to iden-
tify all molecular alterations (genomic or not) of cancer that
can shape response to treatments [20]. Increased optimism
in recent years has been generated by technical improve-
ments and decreased costs of next generation sequencing
(NGS). It is now possible, at least in theory, to use gene
panels of increasing complexity to identify all driver genetic
mutations by NGS and match these mutations to an ever
increasing number of approved or experimental drugs cap-
able of targeting these mutations [21, 22]. Applying of this
concept is a highly challenging task because of the com-
plexity to accumulate, store, interpret and standardize the
data required to leverage genomic data that improves pa-
tient treatment [23]. However, this is not yet feasible in clin-
ical practice at the present time and only few organizations
have been able to use this approach experimentally with en-
couraging results [21, 22]. In addition to a highly qualified
bioinformatic capable of elaborating data, it is also neces-
sary to assemble and coordinate of a multidisciplinary
tumor board comprising oncologists, radiologists, patholo-
gists, geneticists, statisticians, mathematicians, as well as
partnering up with several pharmaceutical companies to
make their experimental drugs available. Hence, with a few
exceptions, although we are able to identify several genomic
aberrations in metastatic cancer, the utility of this informa-
tion still remains largely elusive [23].
Therefore, at this moment in time we cannot talk of the
realization of a true “precision medicine” approach. This
may be also due to an additional reason, namely the intra-
patient heterogeneity of tumors and the ability of cancer
genomes to evolve dynamically over time and accumulate
different subsets of mutations in different tumor sub-
clones. Sophisticated techniques are able to construct
phylogenetic trees of tumors showing the relationships
among the various patterns of mutations [24]. Different
subclones can change in their relative proportions with
time due to selective pressures, endogenous (e.g. immuno-
surveillance by our immune system), or exogenous (envir-
onmental cues or drug treatments). Nowadays more than
ever, we can observe as a result of the application of se-
quential lines of therapy often lasting years in the same
metastatic patient, that cancer is becoming a chronic dis-
ease. The notion of chronicity means that cancer is con-
tinuously evolving and is genetically very different after
years of therapy far from the time of the initial diagnosis.
From “personalized or precision medicine” to
“liquid dynamic medicine”
One of the most important breakthroughs in the last few
years is that it is now technically possible to follow tumor
evolution in a non-invasive manner by a procedure called
“liquid biopsy” which involves sequencing tumor DNA
fragments known as circulating tumor DNA (ctDNA) in
blood samples [25]. Liquid biopsies are already in use in se-
lected cases for diagnostic purposes (for example the detec-
tion of resistant mutations in EGFR), and we can expect a
dramatic rise of clinical applications, given that they can
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predict disease relapse several weeks before radiological de-
tection of disease recurrence [26]. Hence, we can expect fu-
ture cancer therapies to not only be genomically driven but
also continuously determined by the variations provided by
the results of sequential liquid biopsies capable of tracking
changes of the emerging dominant subclones to be targeted
by the increasing number of matching drugs [27]. On this
basis, and according to Bauman’s definition of “liquid-mod-
ern society” [28] we would like to propose to replace the
expression “personalized or precision medicine” to “liquid
dynamic medicine” which better describes this methodo-
logical approach. “Liquid dynamic medicine” accurately de-
scribes dynamic changes in tumor evolution which imposes
dynamic changes in the therapy to apply, but also based on
the fact that relevant information is present in body fluids.
In the “liquid dynamic medicine” scenario patients (and
their associations) play a central role and are key players as
the information for therapy directly derives from their
blood or other body fluids, to which they are the sole con-
tributors. Also, central to realizing of this scenario is the
capability of building and interrogating biobanks of longitu-
dinal body fluid samples [29]. Moreover we believe that the
“liquid dynamic medicine” approach will apply to the de-
sign and construction of patient-specific cancer vaccines
against neoantigens a new fashionable approach to cancer
therapy [30].
N-of-1 trials as a tool to implement “liquid
dynamic medicine”
Toward the practical realization of this “liquid dynamic
medicine” setting the use of unconventional clinical trials is
required. Conventional phase I-III clinical trials along with
their rigid schemes do fail to respond the need of answering
more questions, more efficiently and in less time. They are
unable to respond to the need of a dynamic therapy in
which the biological features of the disease change with
time and also where every patient, due to the growing com-
plexity of using diagnostic testing will be differentiated from
all the others. One attempt to solve this issue is by the use
of the so called “Master Protocols”, designed to answer
Fig. 1 Liquid dynamic medicine and N-of-1 trial
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multiple questions [31]. PM’s master protocol concept chal-
lenges the traditional clinical trial infrastructure through
evaluating more than one or two treatments in more than
one patient type or disease within the same overall trial
structure. Master protocols include umbrella, basket and
platform trials. Umbrella trials are designed to study tar-
geted therapies in the context of a single disease. Basket tri-
als study a single targeted therapy in the context of
multiple diseases or a disease subtype. Platform trials focus
on multiple targeted therapies in the context of a single dis-
ease in a perpetual manner, allowing therapies to enter or
leave the platform according to a decision algorithm.
We believe however that also Master Protocols are go-
ing to reveal their limitations in the new world of “liquid
dynamic medicine” and extreme personalization of care.
Indeed, in cases where a combination of molecular alter-
ations is very rare, testing the activity and efficacy of inves-
tigational drugs in a sufficient number of patients also
within master protocols will be highly challenging. For ex-
ample, while 5% of patients with a common malignancy
(e.g., breast cancer) may be sufficient to conceive and con-
duct a conventional trial of a new target therapy, enrolling
an adequate number of patients in a timely manner to de-
fine clinical utility would be extremely difficult if the
population in question represented 1% or less of this
population, and virtually impossible if one wishes to ex-
plore the benefits of treatment in rarer neoplasms. How-
ever, this goal could be possible to achieve with studies
focusing on a single person – known as N-of-1 trials –
which aim to study targeted treatments for tumors in indi-
vidual patients (Fig. 1) [32]. The option we propose is to
compare the time-to-disease progression of an individual
cancer patient following treatment with a novel therapy to
the time-to-disease progression for the same patient on
his/her immediately previous treatment [33]. In other
words, in N-of-1 trials the same patient will be the tester
of a new therapy and its control arm.
Conclusion
The increasing knowledge of molecular events in cancer
cells prompted the identification of targeted therapies
which could be able to interfere with tumor growth. A
dynamic chess mate appeared to characterize sequential
molecular events developing between the onset of mech-
anisms of resistance and the identification of new thera-
peutic strategies.
In conclusion, therefore, for testing new oncology
therapies based on in depth genomic characterization of
patient’ tumors, we propose the use of N-of-1 trials and
the promotion of the term “liquid dynamic medicine”.
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